

**Maryland Board of Pharmacy
Public Board Meeting**

**Agenda
August 18, 2021**

Name	Title	Present	Absent
Bouyoukas, E	Commissioner		
Evans, K.	Commissioner		
Fink, K.	Commissioner		
Hardesty, J.	Commissioner/President		
Geigher, P.	Commissioner		
Leikach, N.	Commissioner/Treasurer		
Morgan, K.	Commissioner		
Oliver, B	Commissioner		
Rusinko, K.	Commissioner/Secretary		
Singal, S.	Commissioner		
Vasquez, J.	Commissioner		
Yankellow, E.	Commissioner		
Bethman, L.	Board Counsel		
Felter, B.	Board Counsel		
Speights-Napata, D.	Executive Director		
Fields, E.	Deputy Director /Operations		
James, D.	Licensing Manager		
Leak, T.	Compliance Director		
Reed, J.	Legislative Liaison		
Chew, C.	Enforcement Compliance Auditor		

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)
---------	-------------------	------------	-------------------------------

I. Executive Committee Report(s)	<p>A.) J. Hardesty, Board President</p> <p>B.) K. Rusinko, Secretary</p>	<p><i>Members of the Board with a conflict of interest relating to any item on the agenda are advised to notify the Board at this time or when the issue is addressed in the agenda.</i></p> <ol style="list-style-type: none"> 1. Call to Order 2. Sign-in Introduction and of meeting attendees – <i>(Please indicate on sign-in sheet if you are requesting CE Units for attendance)</i> 3. Distribution of Agenda and packet materials 4. Review and approve June 2021 Public Meeting Minutes 											
II. A. Executive Director Report	D. Speights-Napata, Executive Director	<ol style="list-style-type: none"> 1. Staffing Update 2. Meeting Update 3. COVID Policy Update 											
B. New Business	J. Hardesty, Board President	<ol style="list-style-type: none"> 1. None 											
C. Operations	E. Fields, Deputy Director/ Operations	<ol style="list-style-type: none"> 1. Procurement and Budget Updates <ol style="list-style-type: none"> a: August 2021 Financial Statements 2. Management Information Systems (MIS) Unit Updates <ol style="list-style-type: none"> a: None 											
D. Licensing	E. Bouyoukas, Commissioner	<ol style="list-style-type: none"> 1. Unit Updates 2. Monthly Statistics <table border="1" data-bbox="751 1263 1367 1344"> <thead> <tr> <th data-bbox="751 1263 905 1289">License Type</th> <th data-bbox="905 1263 1058 1289">New</th> <th data-bbox="1058 1263 1211 1289">Renewed</th> <th data-bbox="1211 1263 1367 1289">Reinstated</th> <th data-bbox="1367 1263 1467 1289">Total</th> </tr> </thead> <tbody> <tr> <td data-bbox="751 1289 905 1344"></td> <td data-bbox="905 1289 1058 1344"></td> <td data-bbox="1058 1289 1211 1344"></td> <td data-bbox="1211 1289 1367 1344"></td> <td data-bbox="1367 1289 1467 1344"></td> </tr> </tbody> </table> 	License Type	New	Renewed	Reinstated	Total						
License Type	New	Renewed	Reinstated	Total									

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)
---------	-------------------	------------	-------------------------------

		<table border="1"> <tbody> <tr> <td data-bbox="751 256 905 331">Distributor</td> <td data-bbox="905 256 1058 331">13</td> <td data-bbox="1058 256 1211 331">94</td> <td data-bbox="1211 256 1365 331">0</td> <td data-bbox="1365 256 1518 331">1,510</td> </tr> <tr> <td data-bbox="751 331 905 406">Pharmacy</td> <td data-bbox="905 331 1058 406">9</td> <td data-bbox="1058 331 1211 406">0</td> <td data-bbox="1211 331 1365 406">0</td> <td data-bbox="1365 331 1518 406">2,092</td> </tr> <tr> <td data-bbox="751 406 905 480">Pharmacist</td> <td data-bbox="905 406 1058 480">88</td> <td data-bbox="1058 406 1211 480">455</td> <td data-bbox="1211 406 1365 480">0</td> <td data-bbox="1365 406 1518 480">12,704</td> </tr> <tr> <td data-bbox="751 480 905 555">Vaccination</td> <td data-bbox="905 480 1058 555">27</td> <td data-bbox="1058 480 1211 555">111</td> <td data-bbox="1211 480 1365 555">0</td> <td data-bbox="1365 480 1518 555">5,486</td> </tr> <tr> <td data-bbox="751 555 905 690">Pharmacy Intern - Graduate</td> <td data-bbox="905 555 1058 690">7</td> <td data-bbox="1058 555 1211 690">0</td> <td data-bbox="1211 555 1365 690">0</td> <td data-bbox="1365 555 1518 690">44</td> </tr> <tr> <td data-bbox="751 690 905 802">Pharmacy Intern - Student</td> <td data-bbox="905 690 1058 802">13</td> <td data-bbox="1058 690 1211 802">94</td> <td data-bbox="1211 690 1365 802">0</td> <td data-bbox="1365 690 1518 802">639</td> </tr> <tr> <td data-bbox="751 802 905 876">Pharmacy Technician</td> <td data-bbox="905 802 1058 876">147</td> <td data-bbox="1058 802 1211 876">282</td> <td data-bbox="1211 802 1365 876">3</td> <td data-bbox="1365 802 1518 876">10,108</td> </tr> <tr> <td data-bbox="751 876 905 989">Pharmacy Technician-Student</td> <td data-bbox="905 876 1058 989">0</td> <td data-bbox="1058 876 1211 989">0</td> <td data-bbox="1211 876 1365 989">0</td> <td data-bbox="1365 876 1518 989">54</td> </tr> <tr> <td data-bbox="751 989 905 1063">TOTAL</td> <td data-bbox="905 989 1058 1063">333</td> <td data-bbox="1058 989 1211 1063">901</td> <td data-bbox="1211 989 1365 1063">3</td> <td data-bbox="1365 989 1518 1063">32,894</td> </tr> </tbody> </table>	Distributor	13	94	0	1,510	Pharmacy	9	0	0	2,092	Pharmacist	88	455	0	12,704	Vaccination	27	111	0	5,486	Pharmacy Intern - Graduate	7	0	0	44	Pharmacy Intern - Student	13	94	0	639	Pharmacy Technician	147	282	3	10,108	Pharmacy Technician-Student	0	0	0	54	TOTAL	333	901	3	32,894	
Distributor	13	94	0	1,510																																												
Pharmacy	9	0	0	2,092																																												
Pharmacist	88	455	0	12,704																																												
Vaccination	27	111	0	5,486																																												
Pharmacy Intern - Graduate	7	0	0	44																																												
Pharmacy Intern - Student	13	94	0	639																																												
Pharmacy Technician	147	282	3	10,108																																												
Pharmacy Technician-Student	0	0	0	54																																												
TOTAL	333	901	3	32,894																																												
E. Compliance	T. Leak, Compliance Director	<p>1. Unit Updates</p> <p>2. Monthly Statistics</p> <p>Complaints & Investigations:</p> <p>New Complaints – 22</p> <ul style="list-style-type: none"> • Medication Error - 2 • Employee Pilferage – 1 																																														

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)
		<ul style="list-style-type: none"> • Disciplinary Action in Another State – 1 • Unprofessional Conduct – 1 • Dispensing Error – 1 • Refusal to Fill – 5 • Customer Service - 3 • Inspection Issues – 6 • Distribution Without a Permit – 2 <p>Resolved (Including Carryover) – 27 Actions within Goal – 17/27 Final disciplinary actions taken – 0 Summary Actions Taken – 0 Average days to complete – 0</p> <p>Inspections: Total - 78</p> <p>Annual Regulatory Inspections - 50 COVID Administration Site Inspections - 15 Narcotic Audit Follow Ups - 0</p> <p>Opening Inspections - 7 Closing Inspections - 5 Relocation/Change of Ownership Inspections - 1 Board Special Investigation Inspections – 0</p>	
F. Legislation & Regulations	J. Reed, Legislative Liaison	<p><u>Regulations</u> None</p> <p><u>Legislation</u></p>	F. Legislation & Regulations

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)
---------	-------------------	------------	-------------------------------

		None	
<p>III. Committee Reports</p> <p>A. Practice Committee</p>	<p>Evans, K. Commissioner</p>	<p>QUESTION from J. Pasay, Laboratory Scientist Surveyor: USP 797 requires the media fill to “simulate the most challenging or stressful conditions encountered during compounding of” low, medium and/or high risk compounding. NABP said that they ask the pharmacist what they believe is the most complicated compounding process and then confirm if the pharmacy is doing that for its media fill testing. This will be new to our pharmacies, as most do just a quick low risk kit that just involves moving media between vials, they do not include their ACD/syringe pump, or simulate large batches. How does the Board want to enforce this?</p> <p>PROPOSED RESPONSE: As the Board generally recognizes USP 797 standards, pharmacies are strongly encouraged to conduct their media-fill tests to reflect the most challenging and stressful conditions encountered during compounding. In addition, compounding staff who utilize automated compounding devices (and other compounding equipment) to prepare sterile drug formulations shall demonstrate their media-fill competency on applicable equipment.</p>	

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)
---------	-------------------	------------	-------------------------------

<p>B. Licensing Committee</p>	<p>K. Rusinko, Chair</p>	<p>1. Review of Pharmacist Applications</p> <p>a. 129577 - Applicant is requesting approval to use her MPJE score that expired 02/10/2019 in order for her license to be issued. Due to deaths and ill health of her family she was not able to take the NAPLEX exam before the expiration of her MPJE score. <i>Committee recommendation extend MPJE score for 6 month</i></p> <p>b. 128811 - Applicant is requesting approval for a 6th attempt to pass the MPJE. <i>Committee recommendation to approve</i></p> <p>c. SPK –Pharmacist is request waiver of the reinstatement process and to have the ability to renew online. <i>Committee recommendation, approve, can renew online</i></p> <p>d. RF - Pharmacist is requesting approval to renew online and a waiver of the reinstatement fee. The pharmacist insists she did not receive a renewal notice. <i>Committee recommendation, approve, can renew online</i></p> <p>3. <i>Review of Intern Applications: NONE</i></p> <p>4. Review of Technician Applications: NONE</p> <p>5. Review of Distributor Applications: NONE</p> <p>6. Review of Pharmacy Applications: NONE</p> <p>7. Review of Pharmacy Technicians Training Programs: NONE</p> <p>8. NEW BUSINESS:</p>	
--------------------------------------	---------------------------------	--	--

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)
---------	-------------------	------------	-------------------------------

		<p>a. GKK - Expected pharmacist licensure applicant would like confirmation that the hours obtained while working at United States Pharmacopeia (USP) under the direct supervision of licensed pharmacists would meet the 1,560 intern hours' requirement. <i>Committee recommendation: The hours working as an intern since registering as an intern will count under COMAR 10.34.02.05. Need 1560 hours as a registered intern.</i></p> <p>b. AA - Registrant is requesting a 3-month extension of her Intern Registration so she may continue to work while waiting to retake the MPJE. <i>Committee recommendation: Deny, licensee can be registered as a technician if they meet the requirements.</i></p> <p>c. BA - Inquirer is requesting the Board reconsiders the denial of his request to waive the FPGECC. Request was denied July 2021. <i>Committee recommendation: Deny</i></p> <p>d. OWA - Future applicant is requesting a waiver of 20 of the required 1,560 hours for foreign graduates. He has completed a total of 1,540 hours in VA. <i>Committee recommendation: Waive the 20 hours</i></p> <p>e. MA - Foreign graduate is requesting approval to complete his intern hours using the Technician registration. <i>Committee recommendation: Approve. Must complete the pharmacy affidavit form for the hours to count</i></p> <p>f. Theresa Childs - Permit holder is requesting Board approval to continue operations remotely. Due to COVID, operations were moved to remote. The</p>	
--	--	--	--

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)
		<p>Pharmacist would be available via phone and email during normal business hours. In person visits would require 24 notice.</p> <p><i>Committee recommendation: Approve to operate remotely as long as one staff is on site during hours of operation, to allow for unannounced inspections.</i></p> <p>g. Israel Ayegbusi - Pharmacist is requesting guidance from the Board to create a business with the following operations: The business will be an online/virtual DIS platform where consumers, patients and healthcare professionals could ask questions/seek clarifications about drugs/medications use and get professional feedback from RpHs.</p> <p><i>Committee recommendation: As described, they are working within scope of practice. A Pharmacy permit is not needed.</i></p> <p>h. Fresenius Kabi - Company is requesting that Wisconsin be granted deemed state status. Company also requested to begin operations while DDA accreditation is pending.</p> <p><i>Committee recommendation deny both requests</i></p>	
C. Public Relations Committee	E. Yankellow, Chair	Public Relations Committee Update:	
D. Disciplinary	J. Hardesty, Chair	Disciplinary Committee Update	
E. Emergency Preparedness Task Force	N. Leikach, Chair	Emergency Preparedness Task Force Update	

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)
---------	-------------------	------------	-------------------------------

IV. Other Business & FYI	J. Hardesty, President		
V. Adjournment	J. Hardesty, President	<p>A. The Public Meeting was adjourned.</p> <p>B. J. Hardesty convened a Closed Public Session to conduct a medical review committee evaluation of confidential applications.</p> <p>C. The Closed Public Session was adjourned. Immediately thereafter, K. Morgan convened an Administrative Session for purposes of discussing confidential disciplinary cases.</p> <p>D. With the exception of cases requiring recusals, the Board members present at the Public Meeting continued to participate in the Closed Public Session and the Administrative Session.</p>	